ArticleOncology and therapy2025

First-Line Tislelizumab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: PD-L1 ≥ 50% Subgroup Analysis from the RATIONALE-304 Trial.

Shun Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.